Screener
Immix Biopharma, Inc. IMMX Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Immix Biopharma, Inc.’s 10-K/A, filed March 27, 2026.
- Filed
- Mar 27, 2026, 5:28 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001493152-26-013298
| Line item | 2025 / For the Years Ended December 31, | 2024 / For the Years Ended December 31, |
|---|---|---|
| Interest income | 555,526 | 1,017,354 |
| Total other income | 555,526 | 1,017,354 |
| Loss before provision for income taxes | (29,400,889) | (21,657,326) |
| Provision for income taxes | 37,724 | 41,037 |
| Net loss | (29,438,613) | (21,698,363) |
| Net loss attributable to non-controlling interests | - | 84,987 |
| Net loss attributable to Immix Biopharma, Inc. common stockholders | (29,438,613) | (21,613,376) |
| Other comprehensive income (loss): |
Document
FAQ
- What is Immix Biopharma, Inc.'s income tax?
- Immix Biopharma, Inc. (IMMX) reported income tax of $11.27K in Q4 2025.
- How has Immix Biopharma, Inc.'s income tax changed year-over-year?
- Immix Biopharma, Inc.'s income tax increased by 4.5% year-over-year, from $10.79K to $11.27K.
- What is the long-term trend for Immix Biopharma, Inc.'s income tax?
- Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s income tax has grown at a 58.3% compound annual growth rate (CAGR), from $6.01K to $37.72K.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Immix Biopharma, Inc.'s income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude